N-benzyl-N-chloroformamide | 140669-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-N-chloroformamide
• CAS: 140669-90-5
• 化学式: C₈H₈ClNO
• 分子量: 169.611
• InChiKey: SVPYFVQRPBLXMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  戊烯 、 N-benzyl-N-chloroformamide 在 chromium dichloride 作用下， 以42%的产率得到N-benzyl-N-(2-chloropentyl)formamide
  参考文献：
  名称：

  Photolytic and chromium(II)-promoted addition reactions of N-halogenoformamides with alkenes

  摘要：

  Formamidyl radicals (HCONR) do not intramolecularly abstract hydrogen or cyclise onto aromatic rings, but do add intermolecularly to alkenes. The photolytic addition of N-halogenoformamides to alkenes is inhibited by N-alkylation. However, N-alkyl-N-halogenoformamides add to alkenes in the presence of chromium(II) species. The addition of N-halogenoformamides to alkenes occurs regiospecifically with formamidyl bonding to the less substituted terminus of the alkene. The adducts obtained from N-alkylformamidyls exist as mixtures of rotameric isomers whose configurations have been assigned. The reactivity of the formamidyl radical has been discussed in terms of its conformation and electronic state.

  DOI：

  10.1039/p19920000627
• 作为产物：
  描述：

  N-苄基甲酰胺 在 三氯异氰尿酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以95%的产率得到N-benzyl-N-chloroformamide
  参考文献：
  名称：

  酰胺和氨基甲酸酯高效 N-氯化的简单方案

  摘要：

  各种酰胺、内酰胺和氨基甲酸酯与非常便宜的三氯异氰尿酸在非常温和的条件下有效地进行 N-氯化。对于游离氨基酸的氨基甲酸酯的 N-氯化也观察到了极好的结果。

  DOI：

  10.1055/s-2004-836061

文献信息

• [EN] PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV<br/>[FR] COMPOSES PYRIDINES UTILISES COMME INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005042488A1

  公开（公告）日：2005-05-12

  A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.

  该化合物的化学式表示为其中R1和R2相同或不同，每个都是可选择取代的碳氢基团或可选择取代的羟基团；R3是可选择取代的芳香基团；R4是可选择取代的氨基团；L是二价链状碳氢基团；Q是键或二价链状碳氢基团；X是氢原子、氰基、硝基、酰基、取代的羟基团、可选择取代的硫醇基团、可选择取代的氨基团或可选择取代的环状基团；但当X是乙氧羰基团时，Q为二价链状碳氢基团。该化合物具有肽酶抑制作用，可用作糖尿病等疾病的预防或治疗药物，并在功效、作用持续时间、特异性、毒性较低等方面具有优越性。
• Pyridine compounds as inhibitors of dipeptidyl peptidase IV
  申请人：Oi Satoru

  公开号：US20070037807A1

  公开（公告）日：2007-02-15

  A compound represented by the formula wherein R 1 and R 2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R 3 is an optionally substituted aromatic group; R 4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.

  该化合物的化学式为其中R1和R2是相同或不同的可选择取代的烃基或可选择取代的羟基；R3是可选择取代的芳香基；R4是可选择取代的氨基；L是二价链烃基；Q是键或二价链烃基；X是氢原子、氰基、硝基、酰基、可选择取代的羟基、可选择取代的硫醇基、可选择取代的氨基或可选择取代的环状基；但当X是乙氧羰基时，Q是二价链烃基。该化合物具有肽酶抑制作用，可用作预防或治疗糖尿病等药物，具有优异的疗效、持续时间、特异性、低毒性等特点。
• NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES
  申请人：Fensholdt Jef

  公开号：US20100317582A1

  公开（公告）日：2010-12-16

  The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及新的环烃化合物及其衍生物，其制备方法，以及将这些化合物用作药物、治疗用化合物、包含这些化合物的药物组合物、使用这些化合物治疗疾病的方法，以及将这些化合物用于药物制造的用途。
• (d)-6-Fluoro-2,3-dihydro-2',5'-dioxo-spiro[1H-1-Benzopyran-4,4'-imidazolidine]-2-carboxamide derivatives, process for the preparation and use of the derivatives
  申请人：SANWA KAGAKU KENKYUSHO CO., LTD.

  公开号：EP0336416A1

  公开（公告）日：1989-10-11

  Hydantoin derivatives of the formula wherein Ra and Rb are same or different, each being hydrogen atom, alkanoyl, substituted or none-substituted aroyl, heteroaroyl, alkoxycarbonyl, substituted or none-substituted aralkoxycarbonyl, aryloxycarbonyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, substituted or none-substituted N-aralkylcarbamoyl, alkoxyalkyl, 1-(acyloxy)-alkyl, alkylmercapto, substituted or none-substituted arylmercapto, alkylsulfinyl, substituted or none-substituted arylsulfinyl, alkylsulfonyl or substituted or none-substituted arylsulfonyl, but both of Ra and Rb do not concurrently means hydrogen atom, a process for the preparation of the derivatives, and use thereof as an agent for preventing and curing chronic complications due to diabetes.

  式中的海因衍生物 其中 Ra 和 Rb 相同或不同，各自为氢原子、烷酰基、取代或非取代的芳酰基、杂芳酰基、烷氧基羰基、取代或非取代的芳氧基羰基、芳氧基羰基、N-烷基氨基甲酰基、N,N-二烷基氨基甲酰基、取代或非取代的 N-芳基氨基甲酰基、烷氧基烷基、1-(酰氧基)-烷基、烷基巯基、取代或非取代的芳巯基、烷基亚磺酰基、烷基磺酰基或芳基磺酰基、取代或非取代的芳基巯基、烷基亚磺酰基、取代或非取代的芳基亚磺酰基、烷基磺酰基或取代或非取代的芳基磺酰基，但 Ra 和 Rb 均不同时表示氢原子，这些衍生物的制备方法，以及将其用作预防和治疗糖尿病引起的慢性并发症的药物。
• HETEROCYCLIC COMPOUNDS
  申请人：Ajinomoto Co., Inc.

  公开号：EP1396493A1

  公开（公告）日：2004-03-10

  A pharmaceutical composition containing a heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-α production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-α.

  一种含有式(I)杂环化合物的药物组合物 其中各符号如说明书中所定义）的杂环化合物、其异构体、其溶液或其药学上可接受的盐作为活性成分的药物组合物，具有优异的抑制 TNF-α 生成的作用。因此，它可用于预防或治疗由 TNF-α 的异常产生引起的各种疾病。